Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.49 |
| ▸ | PPIA | P62937 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13332426 | 0.84 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2EPHX1PPIA | |
| SCHEMBL13332431 | 0.82 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2MAPK1PPIA | |
| SCHEMBL13332420 | 0.78 | PPIA (0.56) | NPC1RAB9ASMN1; SMN2MAPK1EPHX1 | |
| SCHEMBL4514409 | 0.75 | POLB (0.50) | NPC1RAB9ASMN1; SMN2MAPK1EPHX1 | |
| SCHEMBL4513190 | 0.74 | HPGD (0.51) | NPC1RAB9ASMN1; SMN2MAPK1EPHX1 | |
| SCHEMBL6646405 | 0.73 | HPGD (0.43) | NPC1RAB9ASMN1; SMN2MAPK1EPHX1 | |
| SCHEMBL13332415 | 0.72 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL3455703 | 0.72 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL4516474 | 0.72 | MAPK1 (0.49) | MAPK1HPGDPOLBKDM4EALDH1A1 | |
| SCHEMBL6643946 | 0.72 | HPGD (0.43) | NPC1RAB9ASMN1; SMN2MAPK1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | P2RY12, P2RY4, P2RY1 | NPC1 3476/4885RAB9A 4041/4885SMN1; SMN2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.